RxDoctor Payments Data

Mildred Caro-Ruiz, MD

Pulmonary Disease · Aguada, PRNPI 1518053438

Payments from drug & device makers

$1,965in general payments, 2019–2025

Across 85 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$924
  • GSK$369
  • Boehringer Ingelheim$220
  • Merck$162
  • United Therapeutics Corporation$55
  • E.r. Squibb & Sons, L.L.C.$54
  • plus $180 from 7 others

What the payments were for

  • Food & beverage$1,94699%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,965 in reported general payments places this provider in the 40th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,118
Medicare patients
26
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate37$486,191
Spiriva RespimatTiotropium Bromide616$333,361
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate650$180,473
Stiolto RespimatTiotropium Br/Olodaterol Hcl275$135,017
Trelegy ElliptaFluticasone/Umeclidin/Vilanter177$119,446
Breztri AerosphereBudesonide/Glycopyr/Formoterol180$117,875
Fluticasone Propionate HfaFluticasone Propionate365$96,648
Breo ElliptaFluticasone/Vilanterol180$74,099
Albuterol Sulfate HfaAlbuterol Sulfate1,704$69,779
Atrovent HfaIpratropium Bromide138$65,856
SymbicortBudesonide/Formoterol Fumarate229$55,617
Combivent RespimatIpratropium/Albuterol Sulfate95$49,270
Qvar RedihalerBeclomethasone Dipropionate109$29,552
Levalbuterol Tartrate HfaLevalbuterol Tartrate217$13,257
Wixela InhubFluticasone Propion/Salmeterol58$10,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$220$1,003,8391,023 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$369$211,294421 claims
AstraZenecaBreztri Aerosphere, Symbicort$924$173,492409 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Aguada

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →